# US 5,700,639 A · Method for the detection of metabolically labelled DNA > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,700,639 A - Document ID: US5700639A - Status: Granted - Kind: A - Application number: 08/257,686 - Filed: 1994-06-09 - Granted: 1997-12-23 - Earliest claimed: 1993-06-12 - Assignees: Boehringer Mannheim GmbH - Inventors: Bernhard Trauth; Matthias Hinzpeter; Clemens Doppler; Eberhard Russmann - Web page: https://patentgrep.com/patent/US5700639A ## CPC - G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites} - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention concerns a method for the non-radioactive detection of metabolically labelled DNA, in one aspect detecting labelled DNA indicative of cell lysis or apoptosis. ## Claims ### Claim 1 Method for measuring DNA synthesis in a cell, comprising: (a) metabolically incorporating a nucleotide analogue into a double stranded DNA of said cell; (b) incubating a cell fraction of said cell containing said double stranded DNA having incorporated therein said nucleotide analogue in the presence of a first antibody specific to DNA to obtain a double stranded DNA-first antibody complex, wherein said first antibody is bound to a solid phase prior to or after said incubating; (c) denaturing or partially degrading said double stranded DNA bound to said first antibody without separating said first antibody from said solid phase, thereby providing denatured DNA or partially degraded DNA bound to said first antibody; (d) contacting said bound denatured or partially degraded DNA with a labeled second antibody specific to said nucleotide analogue under conditions favoring binding of said labelled second antibody to said nucleotide analogue present in said bound denatured or partially degraded DNA, (e) separating the solid phase from reagents in liquid phase; and (f) measuring a level of labelled second antibody on said solid phase or in said liquid phase as a measure of nucleotide analogue incorporation into the DNA of said cell thereby measuring the DNA synthesis of the cell. ### Claim 2 (depends on 1) The method of claim 1, wherein said first antibody is bound to said solid phase prior to said incubating. ### Claim 3 (depends on 1) The method of claim 1, wherein said first antibody is bound to said solid phase after said incubating. ### Claim 4 (depends on 1) The method of claim 1, wherein said nucleotide is 5-bromo-2'-deoxyuridine and said second antibody is specific to bromodeoxyuridine. ### Claim 5 (depends on 1) The method of claim 1, wherein said denaturing or partial degrading comprises treatment with microwaves or an exonuclease. ### Claim 6 (depends on 1) The method of claim 1, wherein said first antibody is biotinylated and said solid phase is coated with streptavidin. ### Claim 7 (depends on 1) The method of claim 1, wherein said cell fraction is a cell culture supernatant of a cell that has been lysed. ### Claim 8 (depends on 1) The method of claim 1, wherein said cell fraction is a cytoplasmic fraction of said cell. ### Claim 9 Method for distinguishing between lytic or apoptotic mechanism of a cytotoxic agent or cell action on a sample of cells comprising: (a) incorporating a nucleotide analogue into the double stranded DNA of a sample of cells in culture medium; (b) contacting said sample having incorporated therein said nucleotide analogue with a cytotoxic agent or cell population for a period of 4 hours or less; (c) separating said sample of cells into a first group and a second group; (d) contacting the first group with an agent that lyses cells by lysing the cell membranes thereof but not the nuclear membrane of said cells, to obtain a cytoplasmic cell fraction and a nuclear fraction; (e) incubating said cytoplasmic cell fraction obtained in step (d) in the presence of a first antibody specific to DNA to obtain a double stranded DNA-first antibody complex, wherein said first antibody is bound to a solid phase prior to or after said incubating; (f) incubating a cell culture supernatant cell fraction from the second group in the presence of a first antibody specific to DNA to obtain a double stranded DNA first antibody complex, wherein said first antibody is bound to a solid phase prior to or after said incubating; (g) for each of the cell fractions from said first and said second groups according to steps (e) and (f): (i) denaturing or partially degrading said double stranded DNA bound to said first antibody without separating said first antibody from said solid phase, thereby providing denatured or partially degraded DNA bound to said first antibody, (ii) contacting said bound denatured or partially degraded DNA with a labeled second antibody specific to said nucleotide analogue under conditions favoring binding to said bound denatured or partially degraded DNA; (iii) separating the solid phase from reagents in liquid phase; (iv) measuring a level of labelled second antibody on said solid phase or in said liquid phase as a measure of a level of DNA in said cell fraction; and (h) comparing the levels of DNA obtained in step (g) (iv) for said cell fractions from said first and second groups, wherein the presence of DNA in both the cytoplasmic cell fraction from the first group and the cell culture supernatant cell fraction from the second group is indicative of a lytic mechanism of action of said cytotoxic agent or cell population and, wherein the presence of DNA only in said cytoplasmic cell fraction from the first group is indicative of an apoptotic mechanism of action of said cytotoxic agent or cell population. ### Claim 10 (depends on 9) The method of claim 9, wherein said first antibody is bound to said solid phase prior to said incubating. ### Claim 11 (depends on 9) The method of claim 9, wherein said first antibody is bound to said solid phase after said incubating. ### Claim 12 (depends on 9) The method of claim 9, wherein said nucleotide is 5-bromo-2'-deoxyuridine and said second antibody is specific to bromodeoxyuridine. ### Claim 13 (depends on 9) The method of claim 9, wherein said denaturing or partially degrading comprises treatment with microwaves or an exonuclease. ### Claim 14 (depends on 9) The method of claim 9, wherein said first antibody biotinylated and said solid phase is coated with streptavidin.